Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs

Expert Opinion on Therapeutic Targets
Kathy A GelatoBernard Haendler

Abstract

Histone deacetylases (HDACs) and DNA methyltransferases (DNMTs) were the first epigenetic targets to be successfully addressed for cancer treatment, but more recently additional families of epigenetic modulators have been the subject of intense research. Potent inhibitors have been identified in several instances and have proven to be invaluable tools for studying these proteins in normal physiology and in disease. Some have now progressed to clinical studies in hematological and solid tumors, and encouraging early results have been reported. This article reviews recent advances regarding the roles of new epigenetic players beyond HDACs and DNMTs in cancer, and discusses the impact of selective chemical probes on unravelling their function. The emerging field of non-coding RNAs (ncRNAs) and ongoing clinical studies with epigenetic drugs and microRNAs (miRNAs) are also addressed. The roles of different epigenetic factors in numerous cancers have been unraveled recently, leading to the initiation of clinical studies. With inhibitors of BET bromodomain proteins, the histone methyltransferases EZH2 and DOT1L, and the histone demethylase LSD1 progressing through clinical trials, and the recognition of the importance of ncRNAs as pot...Continue Reading

References

Jul 16, 2003·Molecular and Cellular Biology·Christophe Pivot-PajotSaadi Khochbin
Aug 29, 2003·The Journal of Steroid Biochemistry and Molecular Biology·Michael R StallcupDagang Chen
Nov 1, 2005·Nature·Jan KrützfeldtMarkus Stoffel
Mar 25, 2006·Nature Reviews. Cancer·Aurora Esquela-Kerscher, Frank J Slack
Jun 7, 2006·Proceedings of the National Academy of Sciences of the United States of America·Lin ZhangGeorge Coukos
Jun 24, 2006·Chemistry & Biology·Min Gyu LeeRamin Shiekhattar
Dec 22, 2006·The Journal of Nutrition·Igor P PogribnySharon A Ross
Mar 22, 2007·International Journal of Cancer. Journal International Du Cancer·Angela BarrettJoyce Taylor-Papadimitriou
Nov 18, 2008·Nature Cell Biology·Martin JanssonNicholas B La Thangue
Feb 17, 2009·Nature Structural & Molecular Biology·Yanqi ChangXiaodong Cheng
Oct 22, 2009·Cell Cycle·Abhinav K Jain, Michelle Craig Barton
Oct 24, 2009·Blood·Ramiro GarzonCarlo M Croce
Nov 4, 2009·The Biochemical Journal·Fangnian WangGerald V Denis
Nov 10, 2009·Annals of Surgical Oncology·Takeshi YokoeMasato Kusunoki
Feb 2, 2010·The Journal of Biological Chemistry·Jing HuangShelley L Berger
Mar 6, 2010·Journal of Applied Physiology·Rajnee Kanwal, Sanjay Gupta
Oct 5, 2010·Nature Reviews. Drug Discovery·Ramiro GarzonCarlo M Croce
Dec 24, 2010·Journal of Gastroenterology and Hepatology·Daisy P F Tsang, Alfred S L Cheng
Jan 20, 2011·Genes & Development·Young-Ho LeeMichael R Stallcup
Mar 4, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Andrew Chase, Nicholas C P Cross
Mar 24, 2011·Molecular Therapy : the Journal of the American Society of Gene Therapy·Phong TrangFrank J Slack
Apr 19, 2011·Genes & Development·Yoichi Shinkai, Makoto Tachibana
May 4, 2011·Proceedings of the National Academy of Sciences of the United States of America·Janine M LamonicaGerd A Blobel
Jul 5, 2011·Genes & Development·Anh Tram Nguyen, Yi Zhang
Jul 12, 2011·Cancer Cell·Kathrin M BerntScott A Armstrong
Jul 12, 2011·Nature Chemical Biology·Masoud VedadiJian Jin
Oct 8, 2011·Nature Reviews. Cancer·Shigetsugu Hatakeyama

❮ Previous
Next ❯

Citations

Mar 12, 2016·Epigenetics : Official Journal of the DNA Methylation Society·John K WienckeKarl T Kelsey
Mar 10, 2017·Expert Opinion on Drug Discovery·Veda PrachayasittikulChanin Nantasenamat
Apr 14, 2017·Journal of Medicinal Chemistry·Léa BouchéBernard Haendler
May 10, 2017·International Journal of Molecular Sciences·Simon J Baumgart, Bernard Haendler
Jan 23, 2018·Omics : a Journal of Integrative Biology·Kevin DzoboM Iqbal Parker
Jul 25, 2019·International Journal of Environmental Research and Public Health·Maria Letizia Motti, Rosaria Meccariello
Jan 10, 2017·Biomolecules·Omar Castillo-AguileraLaurence Goossens
Jul 2, 2020·International Journal of Molecular Sciences·Maria Letizia MottiMaria Vincenza Carriero
May 8, 2018·International Journal of Molecular Sciences·Ekaterina NevedomskayaBernard Haendler
Dec 29, 2020·Frontiers in Oncology·Isabel Castro-PiedrasKevin Pruitt
Mar 17, 2021·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Neda Barzgar BaroughKobra Velaei
Aug 13, 2021·Advanced Science·Siyu WeiYongshuai Jiang
Dec 21, 2017·ACS Medicinal Chemistry Letters·Phillip P SharpChristopher J Burns
Jul 20, 2020·Endocrine, Metabolic & Immune Disorders Drug Targets·Mirazkar D PandareeshKullaiah Byrappa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.